Galera's stock plunges 73% on disappointing test results for lead cancer drug candidate

Galera Therapeutics stock plunged by more than 70% Tuesday after the Malvern biopharmaceutical firm said its lead experimental cancer therapy failed to meet its primary endpoint in late-stage clinical testing.